Work

Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy

Year: 2013

Type: article

Study design: Observational Study

Source: Journal of Thrombosis and Haemostasis

DOI: 10.1111/jth.12309

Authors: M. Blondon, K.L. Wiggins, L.B. Harrington, B.M. Psaty, N.L. Smith

Institutions: University of Washington, University Hospital of Geneva, Group Health Cooperative, Kaiser Permanente Washington Health Research Institute, VA Office of Research and Development, Seattle Epidemiologic Information and Research Center

Language: English

Topic: Menopause: Health Impacts and Treatments

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, National Institutes of Health, National Heart, Lung, and Blood Institute

Awards: G1003575363, G1250789344, Estrogens and pharmacogenetic risks of venous thrombosis in postmenopausal women, G1980873071, Genome-wide case-only study of antihypertensive drug-gene interactions, G2139852533, Atrial Fibrillation: Incidence, Risk Factors, and Genetics, G4747384318, G4770872528, ANTIHYPERTENSIVE DRUG/GENE INTERACTIONS AND CV EVENTS, G702969726, G7453254864, G7601865164, G8472450595, Pharmacologic and pharmacogenetic associations with recurrent venous thrombosis

OpenAlex ID: W2039050608

FWCI: 0.235

Cites: 7

Cited by: 1

Related to: 10